AgeX Therapeutics Inc. (AGE)
$11.10
$-1.50
(-11.90%)
As on 26-Mar-2024 20:00EDT
Market cap
$28 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
5.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-6 Mln
-
ROE
0 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.2
-
Debt to Equity
0.8
-
Book Value
$5.1
-
EPS
$-13.7
-
Face value
--
-
Shares outstanding
2,500,750
8 Years Aggregate
CFO
$-62.28 Mln
EBITDA
$-64.92 Mln
Net Profit
$-88.63 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
| -18.0 | -14.7 | -17.8 | -51.6 | -43.7 | -39.9 | -- |
|
BSE Sensex*
| -9.3 | 2.0 | 0.1 | -5.7 | 6.6 | 8.0 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
| -30.3 | -49.4 | -28.3 | -16.5 | -39.1 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
AgeX Therapeutics (AGE)
|
11.1 | 27.8 | 0.1 | -14.8 | -8,225.6 | 252.1 | -- | 5.1 |
| 32.5 | 3,728.2 | 31.1 | -105.4 | -315.3 | -64.2 | -- | 12.8 |
Shareholding Pattern
View DetailsAbout AgeX Therapeutics (AGE)
As of March 26, 2024, AgeX Therapeutics, Inc. was acquired by Serina Therapeutics, Inc., in a reverse merger transaction. AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics... targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California. Read more
-
Chief Financial Officer
Ms. Eun-Jae Park CPA
-
Chief Information Officer
Dr. Ivan Labat
-
Headquarters
Alameda, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for AgeX Therapeutics (AGE)
What is the current share price of AgeX Therapeutics Inc (AGE) Today?
The share price of AgeX Therapeutics Inc (AGE) is $11.10 (NYSE) as of 26-Mar-2024 20:00 EDT. AgeX Therapeutics Inc (AGE) has given a return of -43.72% in the last 3 years.
What is the current PB & PE ratio of AgeX Therapeutics Inc (AGE)?
Since, TTM earnings of AgeX Therapeutics Inc (AGE) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-0.03
|
0.08
|
|
2022
|
-0.06
|
-0.03
|
|
2021
|
-4.05
|
-3.49
|
|
2020
|
-5.22
|
-11.21
|
|
2019
|
-5.53
|
30.89
|
What is the 52 Week High and Low of AgeX Therapeutics Inc (AGE)?
The 52-week high and low of AgeX Therapeutics Inc (AGE) are Rs -- and Rs -- as of 22-Jun-2026.
What is the market cap of AgeX Therapeutics Inc (AGE)?
AgeX Therapeutics Inc (AGE) has a market capitalisation of $ 28 Mln as on 26-Mar-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in AgeX Therapeutics Inc (AGE)?
Before investing in AgeX Therapeutics Inc (AGE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.